



Evidera's Presentations at **ISPOR 2020 Europe Virtual**

WORKSHOPS

Cost-Effectiveness Modelling of Complex Pathways

Faria R, Fenwick E, **Tosh J**, Albrow R

Is Population Adjustment Enough to Reduce Bias in Unanchored Comparisons of Progression-Free Survival in Oncology? The Importance of Dealing with Progression Assessment Time Differences

Kapetanakis V, Bharmal M, **Ishak KJ**

ISSUE PANELS

IP3: The Meaning of Cure - The Search for What?

Ishak KJ, Latimer NR, Ryll B, **Benedict A**

IP8: Integrating Patient Preference into Health Technology Assessment: Can Patient Preferences be Incorporated into the ICER?

de Bekker-Grob E, Bouvy J, Dzingina M, **Marsh K**

PODIUM PRESENTATION

CV2: Patients' Preferences for Once-Daily Oral Versus Once-Weekly Injectable Diabetes Medications: The REVISE Study

Boye K, **Ross M**, Mody R, Konig M, **Gelhorn H**

POSTERS

PBI: BIOLOGICS/BIOSIMILARS/REGENERATIVE MEDICINE

PBI5: An Indirect Comparison of Sustained Remission and FLARE Rates in Responders with NON-Radiographic Axial Spondyloarthritis (NR-AXSPA)

Kiri S, Kim M, **Betts MB**, **Chitnis MK**, **Turner M**, **Fahrback K**, **Tarpey J**

PBI56: Psychometric Validation of the P-SIM, a NOVEL Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis

Warren RB, Gottlieb AB, Merola JF, Garcia L, Cioffi C, Peterson L, **Pelligra C**, Ciaravino V

PCN: CANCER

PCN65: Economic Impact of First-Line (1L) Immunotherapies in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)

Sarri G, **Freitag A**, **Kazmierska P**, Lin B, Pawar V, Zhang X

PCN66: The Health Economic IMPACT of Number of Cancer Types Detectable by a MULTI-Cancer EARLY Detection (MCED) Test

Tafazzoli A, Quon P, **Shaul A**, **Chavan A**, Chung KC, Kansal A, Fendrick AM, Ramsey SD

PCN71: Cost-Effectiveness of Brentuximab Vedotin for the Frontline Treatment of Peripheral T-Cell Lymphomas in Canada

Zou D, Lee J, Kansal A, Ma W, **Harris M**, Lisano J, Fenton K, Yu-Isenberg K

PCN79: Modeling Approaches in Cost-Effectiveness Analysis (CEA) of First-Line (1L) Immuno-Oncology (IO) Therapies in Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR).

Kongnakorn T, Walker A, Sarri G, **Freitag A**, **Marczell K**, **Kazmierska P**, Masters E, Pawar V, Zhang X

PCN107: Considerations and Challenges for Economic Modeling in NON-Metastatic NON-SMALL CELL LUNG Cancer (NMNSCLC)

Milev S, **Harris M**, Quon P, Vo L, McKenna M, **Sun A**, Chaudhary MA, Penrod JR, **Sorensen S**

PCN154: Budget Impact Analysis of Subcutaneous Daratumumab for the Treatment of Patients with Multiple Myeloma in Sweden

Toro-Diaz H, **Li S**, Morano R, Tambour M, Dansk V, Lam A, Slavcev M

PCN182: Estimating the Number of US Patients with Multiple Myeloma (MM) at 5 or More Lines of Treatment (LOT)

Nikolaou A, Maiese EM, Samyshkin Y, Sansbury L, **Oguz M**, **Cid Ruzafa J**, **Sapra S**, **Kapoor R**, Wang F

PCN187: Design Innovation for Efficient Post-Approval Drug Utilization and Effectiveness Studies

Saragoussi D, **Rouleau A**, **Capart P**, **Deveras CC**, **Brett N**, **Ognar R**, **Gazay H**, **Payne K**

PCN293: Understanding Real-World Experiences and Impacts of COVID-19 on Patients with Breast Cancer: A Social MEDIA Listening Analysis

Halhol S, **Raluy-Callado M**, **Oguz M**, **Booth A**

PCN302: Using Health Related Social MEDIA to Understand Experiences of Adults with LUNG Cancer in the Era of Immune-Oncology and Targeted Therapies

Booth A, **Manson S**, **Halhol S**, **Merinopoulou E**, **Raluy-Callado M**, **Hareendran A**, **Knoll S**

PCN319: A Systematic Review of Discrete Choice Experiments in Oncology: Status-Quo and Implications

Collacott H, **Soekhai V**, **Thomas C**, **Brooks A**, **Brookes E**, **Lo R**, **Mulnick S**, **Heidenreich S**

PDB: DIABETES/ENDOCRINE/METABOLIC DISORDERS

PDB68: Maximum-Likelihood Estimation of Transition Probabilities between Fibrosis Stages in Nonalcoholic Steatohepatitis (NASH)

Gal P, Rakonczai P

PDB74: Unmet Needs of Patients with Type 2 Diabetes and the Value of Achieving Near Normoglycemia: A Qualitative Study

Gelhorn H, Balantac ZL, Shinde S, Thieu VT, Boye KS

PDB79: Patient and Caregiver Preference Ranking of Glucagon Treatment for Severe Hypoglycaemia from Spain- Initial Results from a Discrete Choice Experiment

Artme E, Mitchell B, Shaffer S, Chua GN, Rentz A

PIH: INDIVIDUAL'S HEALTH

PIH19: Success Factors for a Nice HTA Experience in Paediatrics

James S, Gruber P, Vilu HL, Martin M

PIN: INFECTIOUS DISEASES

PIN11: A Generic Simple Model to Assess Candidate Vaccines in Development

Roiz J, Sutton K, Chapman R

PIN34: COVID 19 - What Is the Health-Economic Economically Justifiable Price of Lockdown?

Gani R, Brown L, Kapoor R

PMU: MULTIPLE DISEASES

PMU37: Towards Joint Decision Making- The Need for a Framework to Address Asymmetrical VALUE

Parkinson M, Olid Gonzalez A

PMU38: Considerations for Companies and Healthcare Systems for Managed Entry Agreements: A Review of the Recent Trends across Italy, Spain and the UK in Oncology

Vanoni C, Parkinson M, Olid Gonzalez A, Iliadi Alexiou A

PMU44: Can Price-Prevalence Trends be Used to Guide the Pricing and Reimbursement Strategy for New Orphan Drugs? A Two-Country Case Study

Vanoni C, Laughlin W, Rakonczai P, Katsoulis IA, Bending MW

PMU55: Methods and Acceptability of Comparator Arms for CAR-T HTA Submission

Chapman R, Kovacs V, Sorensen S

PMU90: Exploring Symptoms, Impacts, and Patient-Reported Outcome (PRO) Measures in Prurigo Nodularis: A Review of the Literature

Chanis R, Dias Barbosa C, Wilson R, Jabbar-Lopez Z, Puellas J, Gabriel S

PMU91: Heterogeneity of Patient Preferences for Low-Dose Aspirin Treatment - Evidence from a Discrete Choice Experiment in Italy

Tervonen T, Vora P, Seo J, Krucien N, Marsh K, Wissinger U, Soriano-Gabarro M

PMU105: Patient Preferences for Systemic Atopic Dermatitis Treatments in the UK, France and Spain: A Discrete Choice Experiment

Thomas C, Raibouaa A, Wollenberg A, Capron J, Krucien N, Karn H, Tervonen T

PND: NEUROLOGICAL DISORDERS

PND57: Cost-Effectiveness Analysis of a Hypothetical Disease Modifying Therapy for Parkinson's Disease

Chandler C, Gal P, Folse H, Chavan A, Ward A

PND103: Patient Preferences for Multiple Sclerosis Treatment during a Phase 3 Trial

Chua GN, Beyer A, Hennessy B, Brooks A, Tervonen T

PNS: NO SPECIFIC DISEASE

PNS10: Research in the COVID-19 Era: Accelerating the Shift in the Research Paradigm from Traditional Towards Digital/Virtual Solutions

Stein D, Baltezgar M

PNS156: Are Surrogate Outcomes Enough for the Reimbursement of Health Technologies? An Umbrella Literature Review.

Freitag A, Sarri G

PNS162: An Initial Framework to Describe and Classify Integrated Scientific Advice Procedures: Trends and Developments

Boss J, Griffiths J, Laughlin W, Vanoni C, Olid Gonzalez A, Bending M

PNS170: An Analysis of NICE Approval Prospects for Drugs with ICERs >£30,000 per QALY Gained

Thomas H, Mitchell C, Papaleontiou L, Sharif S, Rawson K

PNS176: Is the Door for RWE Acceptance in the German HTA Now Open?

Emich H, Schmetz A, Prawitz T, Raluy M

PNS201: A Simple Method of Sampling Ordered Bounded Parameters in Probabilistic Sensitivity Analysis

Litkiewicz M, Nikolaou A

PNS216: Beyond the Statistical Methods- Design Strategies Impacting the Method to Compare Cohorts in Prospective Observational Studies

Yue B, Colby C, Ladouceur M

PNS221: Healthcare Decision-Making Using Real-World Evidence- Many Opportunities, Little Guidance. Results from a Systematic Review of Guidance

Sarri G, Abrams KR, Muszbek N, Debray T

PNS229: Using MIXED Methods to Explore the Content Validity and Importance of Various SLEEP Parameters in a SLEEP Diary Questionnaire

Beyer A, Mannix S, Kleinman L

PRO: RARE & ORPHAN DISEASES

PRO9: What's Clear About Assessing Airway Clearance Techniques in Cystic Fibrosis? A Systematic Literature Review

Milenkovic D, Gomez Espinosa E, Iheanacho I

PRO67: Does Society Support the Prioritisation of High-cost Treatments for Rare Diseases? A Systematic Literature Review

Dodman S, Iheanacho I, Koufopoulou M

PRO100: Analysis of Expert Opinion Informing Model Parameters in NICE Appraisals of Highly Specialised Technologies for Rare Conditions

Tosh J, Masclet A

PRO110: A Framework for Developing a MODEL of Chronic Acid Sphingomyelinase Deficiency

Folse H, Ward A, Chandler C, Fournier M, Sardesai A, Pulikottil-Jacob R

PRS: RESPIRATORY-RELATED DISORDERS

PRS64: Lung Function and Asthma Control in Patients on Medium-to-High-Dose ICS-LABA- A Systematic Review of the Observational Literature

Czira A, Meeraus W, Martin A, Turner M, Birch H, Zhang S

PRS66: The Economic Burden of Adult Asthma That Is Uncontrolled on Medium-to-High-Dose ICS-LABA- A Systematic Literature Review

Czira A, Martin A, Turner M, Meeraus W, Birch H, Zhang S

PRS75: The Severity of Chronic Cough Diary (SCCD)- Development of a Novel Patient-Reported Outcomes Instrument

de la Orden Abad M, Haberland C, Filonenko A, Karn H, Skalicky A, Vernon MK, Hareendran A

PUK: URINARY/KIDNEY DISORDERS

PUK6: Economic Modelling of Chronic Kidney Disease (CKD) Using Estimated Glomerular Filtration RATE (EGFR)- Slope: Effect on CKD Modelling of Acceptance of a New Surrogate Outcome

Marczell K, Gal P, Benedict A, Stavas JM, Coulston J, Caro JJ